Under the alliance, PacificGMP will assist Novavax in developing the capability of manufacturing large quantities of vaccine to accommodate the surge capacity that must be met in the event of a pandemic outbreak of influenza.
PacificGMP will utilize disposable bioprocessing technology to manufacture and produce Novavax’s VLP avian flu vaccine. Use of this disposable bioprocessing technology will allow for faster production, with greatly reduced overall manufacturing costs.
This process also mitigates the possibility for cross-contamination in production which should ultimately result in a VLP avian flu vaccine that will be available to the public in a much shorter time period.
“This agreement with PacificGMP brings another critical capability to Novavax in the development of our H5N1 avian influenza VLP vaccine, and puts Novavax a step closer to servicing the world at large in the event of a pandemic.” said Dr Rahul Singhvi, president and CEO of Novavax.